Posted by Michael Wonder on 03 May 2017
NICE recommends Janssen's first-of-its-kind Crohn's drug Stelara
3 May 2017 - Janssen has announced that it has secured recommendation from NICE for Stelara (ustekinumab) in the indication of moderately to severely active Crohn’s disease in adults who have proved unresponsive to conventional therapy or a TNFα inhibitor.
Stelara presents a new mechanism of action to previous therapies in the indication, as the first human monoclonal antibody for Crohn’s disease to target the interleukin (IL)-12 and IL-23 cytokines.
While the drug is now set to be used on the NHS in England and Wales, NICE’s recommendation specifies that Stelara should be offered as a one option among a range of potential treatments.
